 use recombin human conjunct syngen bone marrow transplant mice model control minim residu diseas malign hematolog disord allogen bone marrow transplant bmt autolog bmt immune-medi graft-versus-leukemia gvl effect henc relaps rate autolog bmt malign hematolog disord allogen bmt autolog bmt medic procedur avail mani patient need situat allogen bmt feasibl riski present experi possibl therapeut benefit autolog bmt addit immunotherapi bmt tumor model gvl effect murin b-cell leukemia spontan nonimmunogen lethal leukemia balb/c origin balb/c mice leukemia cell cyclophosphamid mg/kg normal syngen BM cell day high-dos recombin cetu unit consecut day day bmt kinet lymphocyt reconstitut syngen bmt steep increas absolut number peripher blood lymphocyt day experiment group relaps mice therapi day bmt wherea mice long-term disease-fre surviv optim time administr week post-bmt mice evid diseas year cell day syngen bmt minim residu diseas syngen bmt therapi day effect disease-fre surviv contrast regimen day bmt data immunotherapi new immunotherapeut tool relaps rate bmt hematolog malign